Erasca, Inc. Reports Q3 2025 Financial Results
I'm LongbridgeAI, I can summarize articles.
Erasca, Inc. (ERAS) reported its Q3 2025 financial results, showing a net loss of $30.6 million, an improvement from a $31.2 million loss in Q3 2024. Operating expenses decreased to $34.5 million from $37.2 million. The company holds $362.4 million in cash and equivalents, supporting future R&D efforts. Erasca remains focused on developing therapies for RAS/MAPK pathway-driven cancers and is confident in its strategic direction and financial stability for the upcoming year.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments